Preliminary experience with pure antiestrogens

Clinical Cancer Research

Volumn 7, Issue , 2001, Pages 4369s-4375s

  Howell, Anthony ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL]ESTRADIOL; ANASTROZOLE; ANTIESTROGEN; DROLOXIFENE; FULVESTRANT; IDOXIFENE; MIPROXIFENE PHOSPHATE; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

AGONIST; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; HOT FLUSH; HUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MICE; TISSUE DISTRIBUTION;

EID: 0035667882     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. A new antioestrogenic agent in late breast cancer. An early clinical appraisal of ICI 164, 474
2. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group
3. National Surgical Adjuvant Breast and Bowel Project trials in colon cancer
4. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
5. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: Tamoxifen and raloxifene
6. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
7. Additional benefits of tamoxifen for postmenopausal patients
8. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer
9. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women
10. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
11. Should clinicians be concerned about the carcinogenic potential of tamoxifen?
12. Tamoxifen flare in advanced breast cancer
13. Response after withdrawal of tamoxifen
14. Tamoxifen and thromboembolism
15. Venous thrombosis as a side effect of tamoxifen treatment
16. A new triphenylethylene compound, Fc-1157a. II. Antitumor effects
17. Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer
18. No loss of estrogenic or anti-estrogenic activity after demethylafion of droloxifene (3-OH-tamoxifen)
19. TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors
20. Antiestrogenic activity of DP-TAT-59, an active metabolite of TAT-59 against human breast cancer
21. Discovery and synthesis of [6-hydroxy-3-[4-[2-1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)] benzo[b]thiophene: A novel, highly potent, selective estrogen receptor modulator
22. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels
23. (S)-(+)-4-[7-(2, 2-Dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)- ethoxy]phenyl]-2H-l-benzopyran-3-yl]-phenyl 2, 2-dimethylpropanoate (EM-800): A highly potent, specific, and orally active nonsteroidal antiestrogen
24. ICI 182, 780 (Faslodex): Development of a novel "pure" antiestrogen
25. Pharmacokinetics, pharmacological and anti-tumour effects of the specific antiestrogen ICI 182780 in women with advanced breast cancer
26. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer
27. A potent specific pure antiestrogen with clinical potential
28. ICI 182, 780, a new antioestrogen with clinical potential
29. RU 58668: Further in vitro and in vivo pharmacological data related to its antitumoral activity
30. Basic guide to the mechanisms of antioestrogen action
31. DNA regulatory elements for steroid hormones
32. Estrogen receptor activation function 1 works by binding to p160 coactivator proteins
33. 2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance
34. The novel estrogen receptor-β subtype: Potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens
35. A new actor in the estrogen receptor drama-enter ER-β
36. ER β: Identification and characterization of a novel human estrogen receptor
37. Action of "pure" antiestrogens in inhibiting estrogen receptor action
38. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines
39. Antiuterotrophic effects of a pure antioestrogen, ICI 182, 780: Magnetic resonance imaging of the uterus in ovariectomized monkeys
40. Antiuterotrophic effects of the pure antioestrogen ICI 182, 780 in adult female monkeys (Macaca nemestrina): Quantitative magnetic resonance imaging
41. ICI 182, 780: A pure antiestrogen that affects behaviors and energy balance in rats without acting in the brain
42. The estrogen antagonist ICI 182, 780 reduces cancellous bone volume in female rats
43. The future of pure antioestrogens in clinical breast cancer
44. Anti-proliferative and anti-estrogenic effects of ICI 164, 384 and iCI 182, 780 in 4-OH-tamoxifen-resistant human breast-cancer cells
45. MCF7/LCC2: A 4-hydroxytamoxifen-resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182, 780
46. Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182, 780
47. MCF7/LCC9: An antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182, 780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen
48. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer
49. The effects of ICI 182, 780, a pure anti-oestrogen, on the hypothalamic-pituitary-gonadal axis and on endometrial proliferation in pre-menopausal women
50. Effects of the pure anti-oestrogen ICI 182780 on oestrogen receptors, progesterone receptors and Ki67 antigen in human endometrium in vivo
51. The anti-tumour effects of single-dose long-acting Faslodex (ICI 182, 780) compared with tamoxifen in postmenopausal primary breast cancer patients treated before surgery
52. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer
53. Duration of remission to ICI 182, 780 compared to megestrol acetate in tamoxifen resistant breast cancer
54. ICI 182, 780 (Faslodex) (FAS) 250 mg monthly intramuscular (i.m.) injection shows consistent PK during long-term dosing in postmenopausal women with advanced breast cancer (ABC)
55. The pharmacokinetics of single dose Faslodex™(ICI 182, 780) in postmenopausal primary breast cancer: Relationship with estrogen receptor down regulation
56. A comparison of single-dose pharmacokinetics of Faslodex (fulvestrant) 250 mg when given as either one × 5 ml intramuscular injection or two × 2.5 ml injections in postmenopausal women with advanced breast cancer
57. Comparison of efficacy and tolerabiltiy of fulvestrant (Faslodex™) with anastrazole (Arimidex™) in post-menopausal women with advanced breast cancer (ABC): Preliminary results
58. Faslodex (ICI 182, 780) shows longer duration of response compared with Arimidex (anastrozole) in postmenopausal (PM) women with advanced breast cancer (ABC). Preliminary results of a Phase III North American trial
59. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
60. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study